Amaris Geisler

ORCID: 0000-0001-7376-3779
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Dermatologic Treatments and Research
  • Genital Health and Disease
  • Chemotherapy-related skin toxicity
  • Laser Applications in Dentistry and Medicine
  • Cancer Immunotherapy and Biomarkers
  • Colorectal Cancer Treatments and Studies
  • Photodynamic Therapy Research Studies
  • Skin Protection and Aging
  • Urologic and reproductive health conditions
  • Facial Rejuvenation and Surgery Techniques
  • Urticaria and Related Conditions
  • Nail Diseases and Treatments
  • Urological Disorders and Treatments
  • Pharmaceutical industry and healthcare
  • Diversity and Career in Medicine
  • Obesity and Health Practices
  • Autoimmune Bullous Skin Diseases
  • Cutaneous lymphoproliferative disorders research
  • Skin Diseases and Diabetes
  • Tattoo and Body Piercing Complications
  • Chronic Lymphocytic Leukemia Research
  • Feminist Theory and Gender Studies
  • Cervical Cancer and HPV Research
  • Estrogen and related hormone effects
  • Reconstructive Facial Surgery Techniques

Emory University
2023-2025

City College of New York
2022

CUNY School of Law
2018-2021

Memorial Sloan Kettering Cancer Center
2020-2021

Wake Forest University
2021

VA NY Harbor Healthcare System
2021

SUNY Downstate Health Sciences University
2021

City University of New York
2020

Northwestern University
2018

Immunoglobulin E (IgE) blockade with omalizumab has demonstrated clinical benefit in pruritus-associated dermatoses (e.g. atopic dermatitis, bullous pemphigoid, urticaria). In oncology, cutaneous adverse events (paCAEs) are frequent immune checkpoint inhibitors (CPIs) and targeted anti-human epidermal growth factor receptor 2 (HER2) therapies. Thus, we sought to evaluate the efficacy safety of IgE cancer patients refractory paCAEs related CPIs anti-HER2 agents.Patients included this...

10.1016/j.annonc.2021.02.016 article EN cc-by-nc-nd Annals of Oncology 2021-03-03

Objective To characterize the association between cancer therapies and development of lichen sclerosus (LS) in a case series patients. Methods A retrospective chart review was performed to screen for patients who were diagnosed with LS while undergoing therapy at Memorial Sloan Kettering Cancer Center 2003 2019. Patients excluded if they had been prior starting therapy. Clinical treatment characteristics analyzed. Results The final study sample included 29 female developed setting systemic...

10.1097/lgt.0000000000000870 article EN Journal of Lower Genital Tract Disease 2025-02-06

Vulvar lichen sclerosus (VLS) is a chronic, relapsing, inflammatory dermatosis that has significant impact on patients' quality of life (QoL). While disease severity and associated QoL have been studied, factors with treatment adherence their relation to in VLS remain unexplored.The objectives this study were describe demographics, clinical characteristics, skin-related patients assess the relationship between adherence.This was cross-sectional, single institution, electronic survey study....

10.1159/000530108 article EN Dermatology 2023-01-01

Female genital cutting (FGC), also called female mutilation, is defined as "all procedures involving partial or total removal of the external genitalia other injury to organs whether for cultural, religious, nontherapeutic reasons." FGC can have significant health consequences, including multiple physical and psychological complications, throughout life course. Despite violating numerous human rights existing legal prohibitions, practice continues. In United States, becoming increasingly...

10.1089/jwh.2018.7163 article EN Journal of Women s Health 2018-12-28

Scarring has significant esthetic and functional consequences for patients. A need exists anti-scarring therapeutics. Light emitting diode-red light (LED-RL) been shown to modulate skin fibrosis. The aim of this study is evaluate the safety efficacy LED-RL reduce post-operative scarring. Cutaneous Understanding Red-light Efficacy on was a randomized, mock-controlled, single-blind, dose-ranging, split-face phase II clinical trial. Starting 1 week post-surgery, patients received irradiation...

10.1002/jbio.202100073 article EN cc-by-nc-nd Journal of Biophotonics 2021-03-31

Targeted marketing and media may serve as potential sources of health information for consumers, influencing knowledge, practices, perception, utilization care services. In addition to this vulnerable consumerism, there are barriers healthy consumerism including exposure different or lack thereof, inadequate transportation, proximity stores, cost, products that not suitable all skin types. We conducted a multi-center “Skin Color Skin Care Needs” survey characterize the concerns,...

10.36849/jdd.6557 article EN PubMed 2022-07-01

The incidence of vulvar carcinoma increases with age, though elderly women receive less aggressive cancer therapies and fewer strategies aimed at prevention. Furthermore, dual enrolled in Medicaid-Medicare experience poor survival rates for carcinoma. Herein, we provide recommendations the prevention guidelines multidisciplinary care Prevention can be categorized into primary, secondary, tertiary Primary consists vaccination, secondary screening, is management premalignant early-stage lesions.

10.1097/jw9.0000000000000127 article EN cc-by-nc-nd International Journal of Women’s Dermatology 2024-01-03

Thread lifts are a noninvasive technique for suspending ptotic skin. Previous studies have failed to show long-term efficacy data with absorbable threads.

10.1097/dss.0000000000004521 article EN Dermatologic Surgery 2024-12-11

Physician burnout is a common problem that can have negative ramifications for both physicians and patients. Lack of effective coping mechanisms decreases resilience, which lead to burnout, women may be particularly vulnerable.

10.1016/j.ijwd.2020.06.005 article EN cc-by-nc-nd International Journal of Women’s Dermatology 2020-06-25

‘Adherence’ describes a patient’s role in health-related behaviors, including using recommended medications, attending follow-up appointments, and making lifestyle changes (1,2). Barriers to adhere...

10.1080/09546634.2021.1922571 article EN Journal of Dermatological Treatment 2021-04-28

Epidermal growth factor (EGFR)-inhibitors have emerged as the primary therapy in advanced solid tumor malignancies because of improvement survival with overall favorable side effect profile.However, 50-90% patients treated EGFR-inhibitors develop a follicular or acneiform rash, which can be symptomatic and source psychosocial distress, negatively impacting quality life.As this rash is well-recognized cutaneous toxicity EGFR-inhibitors, treatment algorithm has been proposed for management...

10.36849/jdd.2020.5275 article EN Journal of Drugs in Dermatology 2020-08-01

Starting and maintaining a vitiligo support group can appear to be daunting task. However, with proper planning organization, the process become manageable rewarding. Our guide details reasons start group, how run promote group. Legal protections regarding retention funding are also discussed. The authors have extensive experience leading and/or assisting groups for other disease states we sought out current leaders their valuable insights. Previous research has found that various medical...

10.5070/d328659723 article EN cc-by-nc-nd Dermatology Online Journal 2022-12-29

2632 Background: Immune-related cutaneous adverse events (irCAEs) are the most common and often first toxicity of immune checkpoint inhibitors (CPIs). In general population, irCAEs occur on average within 3.6 weeks treatment initiation commonly manifest as maculopapular rash, lichenoid pruritus. Less is known about these in racial ethnic minority patients. The purpose this study to compare cohorts Caucasian patients at Memorial Sloan Kettering Cancer Center. Methods: Herein, we conducted a...

10.1200/jco.2021.39.15_suppl.2632 article EN Journal of Clinical Oncology 2021-05-20
Coming Soon ...